Wells Fargo analyst Larry Biegelsen raised his price target for Novocure to $58 ahead of the company’s September 25 data presentation from the Phase 2 Stellar study of Optune for mesothelioma. Positive top-line data already disclosed by Novocure shows that Optune added to current standard of care improves survival in mesothelioma patients, Biegelsen tells investors in a research note. The analyst expects FDA approval in 2019 and keeps an Outperform rating on shares of Novocure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.